Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2011

View Archived Issues

Novel phosphodiesterase 10A inhibitors synthesized

Lotus Tissue Repair raises funds to advance treatment for dystrophic epidermolysis bullosa

Johns Hopkins University and Innogene Kalbiotech begin trial for lung cancer vaccine

ISC-4 exhibits safety and antitumor activity in murine model of human colon cancer

Preclinical study supports further evaluation of dovitinib in Waldenstrom's macroglobulinemia

Leukothera shows synergistic activity with chemotherapeutic agents in leukemia cell lines

New lysophospholipid S1P1 receptor agonists presented by Almirall

Roche discloses new glycogen synthase activators

Bristol-Myers Squibb and Innate Pharma enter global agreement for IPH-2102

INV-144 enters phase IIa trial to slow kidney disease in patients with hypertension and diabetes

Novel nuclear receptor related 1 receptor ligands patented by Sanofi

Novel PI3K inhibitors prepared

Dainippon Sumitomo and AstraZeneca claim new Toll-like receptor modulators

Vantia Therapeutics raises funds to develop VA-106483 and VA-111913

Roche discloses novel series of monoamine reuptake inhibitors

Dual mTORC1/mTORC2 inhibition may enhance treatment of acute myeloid leukemia

Metabolic Solutions receives funds from the Alzheimer's Drug Discovery Foundation

Zafgen secures financing for phase II trial in obesity

INNO-206 shows safety in ongoing phase Ib trial in soft tissue sarcoma

IDMC recommmends continuation of phase III VENICE trial of Zaltrap in advanced prostate cancer

Merck KGaA to discontinue development of Toll-like receptor 9 agonist IMO-2055

Amylin Pharmaceuticals, Lilly and Alkermes report on tQT study of Bydureon

Phase III EXIST-1 trial of Afinitor in tuberous sclerosis meets primary endpoint

TMC-435 receives FDA fast track status in chronic hepatitis C genotype 1

Amsterdam Molecular Therapeutics requests reexamination of MAA for gene therapy Glybera

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...